Split-thickness skin grafts (STSG) are commonly required in reconstructive surgery but may cause significant pain. The goal of this investigator-initiated trial is to evaluate the effect of liposomal bupivacaine on donor site pain and opioid consumption. A parallel, randomized, controlled trial of adult acute burn patients with <20% TBSA burns was conducted to evaluate the efficacy of liposomal bupivacaine at STSG donor sites. The control group received standard subcutaneous infiltration of dilute lidocaine solution at the STSG donor site, and the experimental group received dilute liposomal bupivacaine infiltration in a similar fashion. Donor site pain scores and opioid consumption in morphine equivalents (MEE) were evaluated. A total of 25 patients were enrolled in each group. There were no statistical differences in demographic variables, and TBSA was 4.0% in both groups (P = .94). There were no statistical differences in pain scores at any time point postoperatively (mean control range 3.1/10–4.9/10, experimental range 3.3/10–4.3/10, P = .12–.96). There were no statistical differences in opioid consumption at 24, 48, or 72 h postoperatively between the groups (mean control MEE range 49.3–71.1, experimental MEE range 63.6–75.8, P = .34–.85). The average length of stay was 7.7 days in both groups (P = .88). No adverse events occurred in either group. There is no statistical benefit to the use of liposomal bupivacaine for infiltration at STSG donor sites compared to standard of care with respect to pain control, opioid use, or length of stay when evaluated in a randomized, controlled fashion.
The steroid dexamethasone is used intraoperatively to prevent postoperative nausea. Studies of intraoperative steroid use in diabetic patients have shown conflicting effects on blood glucose and complications, and their use has not yet been studied in the burn population. A review of adult diabetic acute burn patients undergoing surgery at a verified burn center from 2012 to 2017 was conducted. Statistical analysis compared those who did and did not receive an intraoperative steroid. A total of 74 patients who underwent 121 operations were identified; steroid was administered in 14.0% of cases. There were no statistically significant differences in preoperative glucose, insulin requirements, TBSA, or hemoglobin A1C. Postoperatively, the steroid group had a 16.7 mg/dl (SD = 11.1) increase in blood glucose (P = .042) and 53.5 unit/24 hour (SD = 28.4) increase in insulin requirement (P = .019), compared with no change in controls. The complication rate in the steroid group was 52.9% compared with 20.1% in controls (P = .003); partial graft loss was the most common complication. Diabetic burn patients who receive intraoperative steroid have increased postoperative blood glucose levels, insulin requirements, and complication rates compared with patients who do not receive steroids. Discussion is warranted to avoid intraoperative steroid in this population.
We reviewed 14 consecutive patients at our ABA-verified burn center who received enzymatic debridement with anacaulase-bcdb (NexoBrid®) from January 2020 to May 2023. These patients, part of the NEXT study, had deep partial or full-thickness burns. We aimed to evaluate NexoBrid’s effect on eschar removal, wound healing, surgical needs, and scar quality.
Background: Large surface area burn injuries compromise skin integrity and are associated with significant morbidity and mortality. Skin autografts are essential for wound healing but are limited in patients with extensive burns due to insufficient donor site availability, resulting in delays in wound coverage. Cultured epidermal autograft (CEA) provides burn wound coverage in patients with extremely limited donor sites, but its success is limited by fragility, lack of basement membrane–anchoring cells, and susceptibility to shear and pressure, particularly over the lower extremities. Methods: We present two adult patients with total body surface area burns greater than 80% who underwent treatment with CEA and external fixation of the lower extremities. Burn wounds were excised and temporarily covered with allograft skin prior to CEA application. A triplanar external fixation device was used to suspend the lower extremities off the bed surface to minimize shear and pressure on CEA-treated areas. Results: Following application, both patients demonstrated near-perfect graft adherence, with wounds healing within four weeks and durable epithelial coverage at 12 weeks. No complications related to external fixation were observed. The use of external fixation to suspend the lower extremities reduced shear forces and improved CEA take. This approach provided stable wound healing, facilitated wound care, and demonstrated excellent functional recovery. Conclusions: External fixation may serve as a valuable adjunct in improving outcomes of CEA in patients with extensive burn injuries involving the lower extremities.